UNIPRINT.NET
UniPrint.net announced today the release of their newest update to their enterprise print management software, UniPrint Infinity Version 10. This update marks the most innovative update to the UniPrint Infinity platform since its creation, with new integrations and intuitive tools to help guide organizations towards digital transformation.
UniPrint Infinity, at its core, is a PDF-based Universal Printer Driver with one web based management platform for secure pull printing, mobile printing, serverless (IP) printing and Cloud enablement. Added features such as High Availability, Statistics and Archiving, and Healthcare Printing Suite allow for even greater redundancy and security.
“As more and more businesses move to a software defined approach to meet their printing needs, UniPrint is a key enabler for our print server solutions. UniPrint Infinity v10 solves all printing concerns under one management platform. It’s a clear game changer in the world of printing in IT,” – Chas Purewall, CEO, Softstream Solutions Ltd
Some of the most exciting new features in V10 include:
- Web Console: User-friendly multi-level online console allowing access to UniPrint’s management console. Allows any browser based device to access the web console without installing any application.
- Security: Multi-level administration allowing members of the admin team different levels of access in managing and supporting the printing infrastructure.
- Mobile Support: Users can locate and release print jobs from their mobile device, through QR codes, NFC and iBeacon.
- User Control: Users can manage their own print jobs sent to the UniPrint VPQ within their user session and through ePRINTit printing to public printing locations.
- Serverless Printing: Supports direct IP printing and allows admin to centrally manage all their desktop, VDI and mobile print environments in one place.
The biggest benefit of v10 is providing customers with choice and flexibility by being print vendor and environmentally agnostic. The update also provides different licensing options, better user experience for ease of use, multiple architecture options, and BYOD options.
“UniPrint saves Capito and our clients’ time and expense. UniPrint is a clear leader in the software-defined print market and we will continue to offer their cloud print solution within our solutions portfolio,” – Robert Pate, Head of Sales and Marketing, Capito
To learn more about UniPrint Infinity V10, contact sales@uniprint.net or try out a 14-day free trial of UniPrint Infinity v10 .
About UniPrint.net
UniPrint Infinity™ products focus on simplifying IT management, improving workflow, reducing costs, and increasing security around enterprise printing operations. It enables system administrators to spend less time managing print-related services while increasing end user workflow.
UniPrint Infinity software optimizes printing functionality, minimizes printer management, improves print security, reduces bandwidth consumption, and enables anywhere, anytime, any device printing across different platforms for end users.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180613005172/en/
Contact:
UniPrint.net
Kate Bradford, 416-503-9800 x8258
Marketing
Specialist
kate.bradford@uniprint.net
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 08:03:00 CEST | Press release
- ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years and older with at least one non-class I mutation in the CFTR gene -- In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom